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The echinoderm microtubule-associated protein-like 
4-anaplastic lymphoma kinase (EML4-ALK) gene fusion 
occurs in 2% to 7% of non–small-cell lung cancer (NSCLC) 
cases1,2 and is typically identified by Vysis ALK Break-Apart 
fluorescent in situ hybridization (FISH) assay. Tumors express-
ing this fusion respond to treatment using crizotinib.1
CASE PRESENTATION
A 43-year-old male never-smoker presented with peri-
cardial tamponade. Pericardio/thoracocentesis yielded 2.5 
liters of fluid; light microscopy was consistent with lung 
adenocarcinoma. No epidermal growth factor receptor muta-
tion or EML4-ALK rearrangement was detected. After talc 
pleurodesis, he was treated with four cycles of cisplatin/peme-
trexed. However, he experienced a progression.
A specimen from the tumor was sent for comprehen-
sive genomic profiling using a next-generation sequenc-
ing (NGS) assay in a Clinical Laboratory Improvement 
Amendments laboratory (Foundation Medicine), identifying 
a complex ALK rearrangement. Several steps were then 
undertaken to characterize better the genomic abnormality. 
FISH testing was negative using standard criteria (Figure 1).
NGS analysis of genomic DNA revealed a complex rear-
rangement of ALK, involving breakpoints in at least five dif-
ferent genomic loci. One of the breakpoints was in ALK intron 
19, the canonical breakpoint for EML4-ALK fusions. No clear 
fusion product was predicted; we suspected the existence of 
multiple transcript products that were not readily identifiable.
We thus sequenced cDNA from the same sample to 
study, both, the expression level of ALK and the structure of 
any potential fusion product. The cDNA sequence demon-
strated that the expressed product of the complex rearrange-
ment was the canonical EML4-ALK fusion gene (EML4 
exons 1–13, ALK exons 20–29). We hypothesized that at the 
genomic level the fused EML4 and ALK genes were sepa-
rated by other small genomic shards; this explained why the 
EML4-ALK fusion was not detected by FISH. This connec-
tive region is likely to be removed during splicing and results 
in a functional EML4-ALK transcript. We next showed a 
39-fold overexpression of exons 20–29 of ALK relative to 
exons 1–19 (Figure 2).
ALK immunohistochemistry was positive, as displayed 
in Figure 1. On the basis of these results, crizotinib was begun. 
Within 2 weeks, the patient reported an improvement in pain in 
the pubic area and in exercise tolerance. Significant improve-
ment was seen on initial computed tomography and positron 
emission tomography scans, and after 4 months, the positron 
emission tomography scan was negative and the chest com-
puted tomography scan showed further shrinkage of the pri-
mary lesion (Response Evaluation Criteria In Solid Tumors 
75%; Figure 3).
DISCUSSION
Approximately 3% to 7% of lung tumors harbor 
ALK fusions 1–6 ALK fusions are more commonly found in 
light smokers (<10 pack-years) and/or never smokers.1,2,4,6,7 
ALK fusions are also associated with younger age 2,6,7 and 
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FIGURE 1.  Panel A, Using a manual fluorescent in situ hybridization technique, paraffin sections were hybridized with fluorescent 
ALK Break-Apart probe (Abbott Molecular, Des Plaines, IL). The specimen displayed an atypical pattern of double 3’ALK signals (red) 
fused with the 5’ALK signal (green), which was classified as negative for ALK gene rearrangement (< 15% of cells with split signals, 
3’ ALK and 5’ ALK signals apart by >2 times signal size or single 3’ ALK signal, 50 cells scored). Panels B, C, and D, ALK immunohis-
tochemistry was performed using a primary antibody (clone D5F3, Cell Signaling Technology, Inc, Danvers, MA). All paraffin tissue 
sections were stained with ALK and were reviewed by two pathologists. The tumor cells have predominantly strong staining (3+) 
in 50% of the tumor cells (lower right). The remaining tumor cells showed (2+) in 30% (lower left) and (1+) in 20% of the tumor 
cells, thus resulting in a histologic score of 230 on a 0–300 scale. The top right is 200× and bottom two panels are 400×.
FIGURE 2. A, Hypothetical structure of rearrangement in genomic DNA (top) complex rearrangement placing EML4 exons 
1–13 upstream of ALK exons 20–29, separated by small genomic shards; RNA (bottom) transcription and splicing remove con-
nective region and generate a canonical EML4-ALK fusion transcript; (B) Expression of ALK as measured by RNA-seq coverage, 
dashed line denotes boundary between exons 19 and 20.
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adenocarcinomas with acinar histology6,7 or signet-ring cells.2 
Recent studies demonstrate that the frequency EML4-ALK 
fusion transcript is detected in 2% to 7% of lung adenocarci-
nomas1,2; these tumors are sensitive to crizotinib.
Many ALK rearrangements have been described in 
NSCLC. Most of these fusion variants comprised various 
portions of the EML4 gene fused with a consistent portion 
of the ALK gene. In addition, non-EML4 fusion partners 
have also been identified, including KIF5B and TFG.3
The novel rearrangement identified in this case is 
complex and was not detected by the Break-Apart FISH assay. 
NGS showed that the patient’s tumor harbored a complex 
EML4-ALK rearrangement at the genomic level. Clinical 
and radiographic evidence confirmed a rapid response to 
crizotinib. NGS should be considered in NSCLC patients 
with high likelihood of a driver kinase alteration when none is 
identified by other methods.
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FIGURE 3. A, Chest and (B) pelvic positron emission tomographic computed tomographic scans before, after 4 weeks, and after 
4 months of crizotinib.
